Orchestra BioMed Holdings, Inc. (OBIO) Form 10-Q — Aug 10, 2026
Orchestra BioMed's Q2 2026 net loss widened to $23.8 million from $19.4 million a year earlier, bringing the six-month loss to $44.4 million, as R&D spending rose to $16.6 million in the quarter ahead of targeted BACKBEAT Trial enrollment completion by the end of Q3 2026. Liquidity stands at $110.0 million in cash and marketable securities, and management concluded this is sufficient to fund operations for at least one year.
Key figures
- Revenue
- 198000
- Revenue Yoy
- -88% (6M 2026 $0.198M vs 6M 2025 $1.704M)
- Cash Position
- $110.0 million total, comprising $20.5 million cash and equivalents and $89.5 million marketable securities
- Shares Outstanding
- 60105049
- Q2 2025 revenue
- 836000
- Q2 2026 revenue
- 88000
- Rd expense 6m 2026
- 32371000
- Rd expense q2 2026
- 16590000
- Accumulated deficit
- 407025000
- Stockholders equity
- 19323000
- Marketable securities
- 89491000
- Virtue trial patients
- 740
- Atm remaining capacity
- 92400000
- Medtronic note balance
- 20442000
- Backbeat trial patients
- 284
- Ligand royalty liability
- 34593000
- Cash and cash equivalents
- 20472000
- Atm gross proceeds 6m 2026
- 6000000
- Hercules term loan principal
- 15000000
- Royalty effective interest rate
- 21.2%
- Gain on sale strategic investments
- 2300000
- Medtronic note effective interest rate
- 13.2%
Price after filing
1 day: 0.0%7 days: +11.3%30 days: +28.1%
Close on the filing date to close N calendar days later (from $4.24). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.